Find Paid Clinical Trials in Iowa

Paid Clinical Trials and Focus Groups

Find Paid Clinical Trials

Paid Clinical Trials in Iowa

Top of Directory » All Locations » United States » Iowa




  • Parent-based Intervention to Increase Safe Teen Driving

    Conditions:   Motor Vehicle Occupant Injury;   Teenaged Driver
    Intervention:   Behavioral: Teen driving intervention
    Sponsors:   University of Iowa;   Blank Children's Hospital
    Recruiting - verified November 2009

  • A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: tocilizumab;   Drug: tocilizumab;   Drug: methotrexate
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • Study of A3309 in Patients With Chronic Idiopathic Constipation

    Conditions:   Constipation;   Chronic Constipation
    Intervention:   Drug: A3309
    Sponsor:   Albireo
    Recruiting - verified November 2009

  • Study of Tissue and Blood Samples From Patients With High-Grade Glioma

    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Genetic: DNA ploidy analysis;   Genetic: fluorescence in situ hybridization;   Genetic: microsatellite instability analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Other: diagnostic laboratory biomarker analysis;   Other: flow cytometry;   Other: immunohistochemistry staining method
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study of Tissue and Blood Samples From Patients With Low-Grade Glioma

    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Genetic: fluorescence in situ hybridization;   Genetic: loss of heterozygosity analysis;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: immunohistochemistry staining method
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia

    Condition:   Leukemia
    Interventions:   Genetic: fluorescence in situ hybridization;   Genetic: mutation analysis;   Genetic: nucleic acid sequencing;   Genetic: polymerase chain reaction;   Genetic: western blotting;   Other: flow cytometry;   Other: laboratory biomarker analysis
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720

    Condition:   Leukemia
    Intervention:   Other: laboratory biomarker analysis
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial

    Condition:   Leukemia
    Interventions:   Genetic: DNA analysis;   Genetic: Southern blotting;   Genetic: cytogenetic analysis;   Genetic: polymerase chain reaction
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Feasibility Study of Omega-3 Fatty Acids in Dialysis Patients

    Condition:   Cardiovascular Disease
    Interventions:   Drug: Omega-3 Acid Ethyl Esters;   Drug: Placebo
    Sponsors:   University of Iowa;   GlaxoSmithKline
    Recruiting - verified October 2009

  • Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)

    Conditions:   Graft-Versus-Host Disease;   Immune System Disorders
    Interventions:   Drug: Mycophenolate Mofetil;   Drug: Placebo
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Newtwork (BMT CTN)
    Not yet recruiting - verified October 2009

  • Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma

    Condition:   Lymphoma
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Behavioral Trial Studying Programmed Training to Improve Advocacy Skills for Individuals With Traumatic Brain Injury

    Condition:   Brain Injuries
    Interventions:   Behavioral: Advocacy training curriculum;   Behavioral: Self-directed
    Sponsor:   Mayo Clinic
    Recruiting - verified October 2009

  • Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis

    Condition:   Leber Congenital Amaurosis Due to RPE65 Mutations
    Intervention:   Biological: AAV2-hRPE65v2
    Sponsors:   Children's Hospital of Philadelphia;   University of Iowa
    Not yet recruiting - verified October 2009

  • Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

    Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group
    Recruiting - verified November 2009

  • TAXUS Libertē Post Approval Study

    Condition:   Coronary Artery Disease
    Interventions:   Device: TAXUS Liberté Paclitaxel-Eluting Coronary Stent;   Drug: prasugrel;   Drug: placebo;   Drug: aspirin
    Sponsors:   Boston Scientific Corporation;   Eli Lilly and Company;   Daiichi Sankyo Inc.
    Not yet recruiting - verified November 2009

  • The Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis to Assess the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

    Condition:   Rheumatoid Arthritis
    Interventions:   Biological: Placebo;   Biological: Certolizumab pegol
    Sponsor:   UCB, Inc.
    Recruiting - verified November 2009

  • A Weight Loss Study in Overweight Men and Women

    Condition:   Obesity
    Interventions:   Drug: LY377604;   Drug: Sibutramine;   Drug: Metoprolol XL;   Drug: Placebo sibutramine;   Drug: Placebo Metoprolol XL;   Drug: Placebo LY377604
    Sponsor:   Eli Lilly and Company
    Recruiting - verified November 2009

  • H1N1 Vaccine at Two Dose Levels in HIV Positive Adults

    Condition:   Influenza
    Intervention:   Biological: Inactivated Influenza H1N1 vaccine
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified October 2009

  • A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)

    Condition:   Atrial Fibrillation
    Interventions:   Drug: Vernakalant;   Drug: Placebo
    Sponsors:   Astellas Pharma Inc;   Cardiome Pharma
    Recruiting - verified November 2009

  • Carboplatin and Paclitaxel Combined With Cetuximab and/or Cixutumumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

    Condition:   Lung Cancer
    Interventions:   Biological: cetuximab;   Biological: cixutumumab;   Drug: carboplatin;   Drug: paclitaxel
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors

    Condition:   Neoplasms
    Interventions:   Drug: R1507;   Drug: RAD001
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine

    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: insulin glargine + preprandial lispro insulin;   Biological: albiglutide + insulin glargine
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain

    Conditions:   Low Back Pain;   Low Back Pain, Recurrent
    Interventions:   Drug: JNJ-42160443;   Drug: JNJ-42160443;   Drug: JNJ-42160443;   Drug: JNJ-42160443;   Drug: Placebo
    Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Recruiting - verified November 2009

  • A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain

    Conditions:   Osteoarthritis;   Osteoarthritis, Hip;   Osteoarthritis, Knee;   Pain;   Arthralgia;   Joint Pain
    Interventions:   Drug: JNJ-42160443;   Drug: Placebo;   Drug: JNJ-42160443;   Drug: JNJ-42160443;   Drug: JNJ-42160443;   Drug: JNJ-42160443
    Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Recruiting - verified November 2009

  • Rheos HOPE4HF Trial

    Condition:   Heart Failure
    Intervention:   Device: Rheos Baroreflex Activation System
    Sponsor:   CVRx, Inc.
    Recruiting - verified August 2009

  • Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy

    Conditions:   Breast Cancer;   Hot Flashes;   Menopausal Symptoms;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Dietary Supplement: flaxseed;   Other: placebo
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus

    Condition:   Subjective Tinnitus
    Interventions:   Drug: Neramexane mesylate;   Drug: Placebo
    Sponsor:   Merz Pharmaceuticals GmbH
    Recruiting - verified November 2009

  • Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease

    Condition:   Gaucher Disease, Type 1
    Intervention:   Drug: velaglucerase alfa
    Sponsor:   Shire Human Genetic Therapies, Inc.
    Available - verified November 2009

  • COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

    Condition:   Myelofibrosis
    Interventions:   Drug: INCB018424;   Drug: Placebo
    Sponsor:   Incyte Corporation
    Recruiting - verified November 2009

  • Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II or Stage III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

    Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
    Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

    Condition:   Lung Cancer
    Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: carboplatin;   Drug: paclitaxel
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Study of Trastuzumab-MCC-DM1 (T-DM1) in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

    Condition:   Metastatic Breast Cancer
    Interventions:   Drug: pertuzumab;   Drug: trastuzumab-MCC-DM1
    Sponsor:   Genentech
    Recruiting - verified October 2009

  • Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage III or Stage IVA Endometrial Cancer

    Condition:   Endometrial Cancer
    Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

    Conditions:   Bladder Cancer;   Prostate Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
    Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: placebo administration
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Subjects With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)

    Conditions:   Primary Hypercholesterolemia;   Mixed Hyperlipidemia
    Interventions:   Drug: SCH 900271;   Drug: SCH 900271;   Drug: SCH 900271;   Drug: SCH 900271;   Drug: SCH 900271;   Drug: Placebo
    Sponsor:   Schering-Plough
    Recruiting - verified October 2009

  • A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

    Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
    Interventions:   Biological: A6;   Other: laboratory biomarker analysis
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma

    Condition:   Asthma
    Interventions:   Drug: QMF149 Twisthaler®;   Drug: Mometasone Twisthaler®
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified November 2009

  • Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary

    Condition:   Carcinoma of Unknown Primary
    Interventions:   Drug: carboplatin;   Drug: everolimus;   Drug: paclitaxel;   Genetic: gene expression analysis;   Other: laboratory biomarker analysis
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Abatacept Versus Adalimumab Head-to-Head

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: Abatacept;   Drug: Adalimumab
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified November 2009

  • 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD)

    Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: NVA237;   Drug: Placebo to NVA;   Drug: Tiotropium
    Sponsor:   Novartis
    Recruiting - verified November 2009

  • Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

    Condition:   Fabry Disease
    Interventions:   Drug: migalastat hydrochloride;   Drug: Placebo
    Sponsor:   Amicus Therapeutics
    Recruiting - verified October 2009

  • Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer

    Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Samples From Patients With Lung Cancer

    Condition:   Lung Cancer
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

    Conditions:   Chordoma;   Desmoid Tumor;   Sarcoma
    Interventions:   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Blood and Bone Marrow Samples From Patients With Myeloma, Waldenstrom's Macroglobulinemia, Amyloidosis, or Monoclonal Gammopathy of Undetermined Significance

    Conditions:   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Precancerous/Nonmalignant Condition
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

    Condition:   Brain and Central Nervous System Tumors
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid Formulation IMVAMUNE® (1x10^8 TCID50) Administered by the Subcutaneous Route and a Lower Dose Liquid Formulation IMVAMUNE® (2x10^7 TCID50) Administered by the Intradermal Route

    Condition:   Variola Major (Smallpox)
    Interventions:   Biological: IMVAMUNE® (liquid, intradermal);   Biological: IMVAMUNE® (liquid, subcutaneous);   Biological: IMVAMUNE® (lyophilized)
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Not yet recruiting - verified October 2009

  • A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency

    Condition:   Overactive Bladder
    Interventions:   Drug: Fesoterodine;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting - verified November 2009

  • Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59

    Condition:   Influenza
    Interventions:   Biological: A/Anhui/05;   Biological: MF-59;   Drug: Placebo
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Not yet recruiting - verified June 2009

  • Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease

    Condition:   Parkinson Disease
    Interventions:   Drug: isradipine cr;   Drug: placebo/ sugar pill
    Sponsors:   The Parkinson Study Group;   Michael J. Fox Foundation;   Northwestern University Dixon Fund
    Recruiting - verified November 2009

    • Menu
    Find Paid Clinical Trials